(GRFS) Grifols - Ratings and Ratios

Grifols, S.A. is a global leader in the development and production of plasma-derived therapies, operating in over 100 countries. The company specializes in producing critical plasma proteins such as immunoglobulins, albumin, and clotting factors to address rare and chronic conditions. Its core products include immunoglobulin for immunodeficiency disorders, albumin for circulatory and liver conditions, and clotting factors for hemophilia. Grifols also offers novel therapies like Fostamatinib, a spleen tyrosine kinase inhibitor, and biological sealants for surgical bleeding control. In addition, the company provides plasma exchange solutions for Alzheimers disease and markets diagnostic equipment and reagents. Its pipeline includes advanced formulations like Xembify pre-filled syringes, Gamunex bags, and FlexBag, as well as research into alpha-1 antitrypsin deficiency and non-cystic fibrosis bronchiectasis. Grifols collaborates with Canadian Blood Services to secure immunoglobulin supplies and has a robust R&D program focused on next-generation plasma-derived therapies. Founded in 1909 and headquartered in Barcelona, Spain, the company has established itself as a pioneer in plasma therapeutics with a strong commitment to innovation and patient care.

Grifols is currently trading at $7.21, above its 20-day SMA of $6.99 but below its 50-day SMA of $7.51 and 200-day SMA of $7.95. This indicates a potential consolidation phase. The ATR of 0.31 suggests moderate volatility, with average daily price swings of approximately 4.3%. The stocks forward P/E of 11.03 signals expectations of earnings growth, while its current P/E of 26.92 reflects its premium valuation. With a market cap of $5.439 billion and a P/S ratio of 0.75, Grifols is positioned as a mid-sized player in the biotechnology sector with a focus on plasma therapeutics.